Editas Medicine, Inc.

EDIT

$3.37

Name : Editas Medicine, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $329,828,640.00

EPSttm : -1.8

Editas Medicine, Inc.

$3.37

5.31%

$0.17

EDIT — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

12.26

Margin Of Safety %

Put/Call OI Ratio

0.3

EPS Next Q Diff

-0.15

EPS Last/This Y

0.74

EPS This/Next Y

0.19

Price

3.19

Target Price

5.68

Analyst Recom

2.23

Performance Q

54.59

Upside

-1,392.5%

Beta

2.16

Ticker: EDIT

17 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-17	EDIT	2.47	0.23	0.39	21009
2026-03-18	EDIT	2.35	0.23	0.08	21092
2026-03-19	EDIT	2.36	0.23	0.76	21135
2026-03-20	EDIT	2.33	0.23	0.00	21155
2026-03-23	EDIT	2.38	0.32	0.25	14477
2026-03-24	EDIT	2.25	0.32	0.32	14665
2026-03-25	EDIT	2.33	0.32	0.38	14664
2026-03-26	EDIT	2.31	0.32	0.04	14825
2026-03-27	EDIT	2.23	0.32	4.22	14836
2026-03-30	EDIT	2.24	0.33	0.01	15090
2026-03-31	EDIT	2.47	0.33	0.37	15155
2026-04-01	EDIT	2.6	0.34	0.02	15375
2026-04-02	EDIT	2.68	0.33	0.08	15682
2026-04-06	EDIT	2.7	0.32	0.01	15834
2026-04-08	EDIT	2.78	0.31	0.41	16258
2026-04-09	EDIT	2.9	0.31	0.19	16380
2026-04-13	EDIT	3.19	0.30	0.08	16652
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

17 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-17	EDIT	2.46	64.6	-	-1.28
2026-03-18	EDIT	2.35	64.6	-	-1.28
2026-03-19	EDIT	2.36	64.6	-	-1.28
2026-03-20	EDIT	2.34	68.2	-	-1.07
2026-03-23	EDIT	2.39	68.2	-	-1.07
2026-03-24	EDIT	2.25	68.2	-	-1.07
2026-03-25	EDIT	2.33	68.2	-	-1.07
2026-03-26	EDIT	2.31	68.2	-	-1.07
2026-03-27	EDIT	2.24	68.2	-	-1.07
2026-03-30	EDIT	2.24	68.2	-	-1.07
2026-03-31	EDIT	2.47	68.2	-	-1.07
2026-04-01	EDIT	2.60	68.2	-	-1.07
2026-04-02	EDIT	2.68	68.2	-	-1.07
2026-04-06	EDIT	2.70	70.8	-	-1.07
2026-04-07	EDIT	2.75	70.8	-	-1.07
2026-04-08	EDIT	2.78	70.8	-	-1.07
2026-04-09	EDIT	2.89	70.8	-	-1.07
2026-04-10	EDIT	2.95	70.8	-	-1.06
2026-04-13	EDIT	3.19	70.8	-	-1.06
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-17	EDIT	-2.56	7.66	12.21
2026-03-18	EDIT	-2.56	7.66	12.21
2026-03-19	EDIT	-2.56	7.66	12.21
2026-03-20	EDIT	-2.56	7.66	12.21
2026-03-23	EDIT	-2.56	7.66	12.21
2026-03-24	EDIT	-2.56	7.66	12.21
2026-03-25	EDIT	-2.56	7.66	11.83
2026-03-26	EDIT	-2.56	7.66	11.83
2026-03-27	EDIT	-2.56	7.66	11.83
2026-03-30	EDIT	-2.56	7.67	11.83
2026-03-31	EDIT	-2.56	7.67	11.83
2026-04-01	EDIT	-2.56	7.67	11.83
2026-04-02	EDIT	-2.56	7.67	11.83
2026-04-06	EDIT	-2.56	7.71	11.83
2026-04-07	EDIT	-2.56	7.71	11.83
2026-04-08	EDIT	-2.56	7.71	11.83
2026-04-09	EDIT	-2.56	7.71	11.83
2026-04-10	EDIT	-2.56	7.71	11.83
2026-04-13	EDIT	-2.56	7.75	12.26
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.06

Avg. EPS Est. Current Quarter

-0.29

Avg. EPS Est. Next Quarter

-0.21

Insider Transactions

-2.56

Institutional Transactions

7.75

Beta

2.16

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

95.6

Max Drawdown 5-Year %

-98.7

Target Price

5.68

P/E

Forward P/E

PEG

P/S

7.73

P/B

11.48

P/Free Cash Flow

EPS

-1.88

Average EPS Est. Cur. Y

-1.06

EPS Next Y. (Est.)

-0.86

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-395.01

Relative Volume

1.38

Return on Equity vs Sector %

-613.9

Return on Equity vs Industry %

-597.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.09

EBIT Estimation

◆ EDIT Healthcare

$3.20

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

20/20

Pullback

2/25

Volume

3/15

Valuation

10/20

TP/AR

1/10

Options

8/10

RSI

Range 1M

99%

Sup Dist

11.6%

🚀

Momentum Growth

Ride accelerating trends

WATCH

Momentum

22/25

Growth

16/30

Estimates

2/20

Inst/Vol

11/15

Options

8/10

EPS Yr

40.5%

EPS NY

9.1%

52W%

61%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +77.5% upside

Quality

7/30

Valuation

14/30

Growth

14/25

Stability

4/10

LT Trend

4/5

Upside

+77.5%

Quality

Editas Medicine, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 87

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

EDIT

Latest News

—

Caricamento notizie per EDIT…

stock quote shares EDIT – Editas Medicine, Inc. Stock Price stock today

news today EDIT – Editas Medicine, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch EDIT – Editas Medicine, Inc. yahoo finance google finance

stock history EDIT – Editas Medicine, Inc. invest stock market

stock prices EDIT premarket after hours

ticker EDIT fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: EDIT

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y